Five European Biotech Stocks Face Pivotal Trial Results in 2026
Summarize this article with:
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the worldAmericas+1 212 318 2000EMEA+44 20 7330 7500Asia Pacific+65 6212 1000Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the worldAmericas+1 212 318 2000EMEA+44 20 7330 7500Asia Pacific+65 6212 1000It’s been a big year for European biotech stocks: Abivax SA soared about 1,300% after successful trial results for a bowel disease drug, Argenx SE was added to the elite Euro Stoxx 50 Index and smaller names including Valneva SE and Inventiva also had impressive rallies.Now, investors in the sector are looking ahead to clinical trial results in areas including obesity, Lyme disease, Crohn’s disease and autoimmune disorders. There’s a lot at stake, as success can translate to huge stock-price gains, put companies on the radar of US investors — and sometimes lead to potential M&A interest from big pharma.